Hypersensitivity incidence after sugammadex administration in healthy subjects

a randomised controlled trial

K. C. Min, P. Bondiskey, V. Schulz, T. Woo, C. Assaid, W. Yu, T. Reynders, R. Declercq, J. McCrea, J. Dennie, N Franklin Adkinson, G. Shepherd, D. E. Gutstein

Research output: Contribution to journalArticle

Abstract

Background: We evaluated the incidence of hypersensitivity or anaphylaxis after repeated single-dose sugammadex administration in non-anaesthetised adults. Methods: In this multicentre, double-blind study (NCT02028065), healthy volunteer subjects were randomised (2:2:1 ratio) to one of three groups to receive three repeated intravenous injections of sugammadex 4 or 16 mg kg−1, or placebo, separated by a ∼5 week intervals. Targeted hypersensitivity assessments were performed 0.5, 4, and 24 h post-dosing, and hypersensitivity signs/symptoms were referred to a blinded independent Adjudication Committee. Anaphylaxis was determined per Sampson (Criterion 1). The primary endpoint was the proportion with confirmed hypersensitivity. Results: Of 375 evaluable subjects, 25 had confirmed hypersensitivity [sugammadex 4 mg kg−1: 10/151 (6.6%); sugammadex 16 mg kg−1: 14/148 (9.5%); placebo: 1/76 (1.3%)]. The differences in incidence rates vs placebo were 5.3% (95% confidence interval: –0.9, 10.7) for sugammadex 4 mg kg−1 and 8.1% (1.7, 14.2) for 16 mg kg−1. Incidence was similar across sugammadex doses and dosing occasions, including in subjects with reactions to previous doses. Three subjects (16 mg kg−1 group) required antihistamines/corticosteroids and discontinued the study, per protocol; symptoms resolved and no subject required epinephrine. One subject with anaphylaxis after the first 16 mg kg−1 dose recovered completely post-treatment. There were no clinically relevant anti-sugammadex antibody or tryptase findings. Conclusions: Hypersensitivity in response to sugammadex administration can occur in healthy subjects without history of previous sugammadex exposure. Hypersensitivity incidence was similar across sugammadex doses and numerically higher than placebo, with no evidence of sensitisation with repeated administration. Hypersensitivity is unlikely to be mediated through sugammadex-specific immunoglobulin G- or E-mediated mast cell stimulation in healthy volunteers. Clinical trial registration: NCT02028065.

Original languageEnglish (US)
Pages (from-to)749-757
Number of pages9
JournalBritish Journal of Anaesthesia
Volume121
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Healthy Volunteers
Hypersensitivity
Randomized Controlled Trials
Incidence
Anaphylaxis
Placebos
Sugammadex
Tryptases
Histamine Antagonists
Double-Blind Method
Mast Cells
Intravenous Injections
Immunoglobulin E
Epinephrine
Signs and Symptoms
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Immunoglobulin G
Clinical Trials
Confidence Intervals

Keywords

  • anaphylaxis
  • hypersensitivity
  • neuromuscular block
  • sugammadex

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Hypersensitivity incidence after sugammadex administration in healthy subjects : a randomised controlled trial. / Min, K. C.; Bondiskey, P.; Schulz, V.; Woo, T.; Assaid, C.; Yu, W.; Reynders, T.; Declercq, R.; McCrea, J.; Dennie, J.; Adkinson, N Franklin; Shepherd, G.; Gutstein, D. E.

In: British Journal of Anaesthesia, Vol. 121, No. 4, 01.10.2018, p. 749-757.

Research output: Contribution to journalArticle

Min, KC, Bondiskey, P, Schulz, V, Woo, T, Assaid, C, Yu, W, Reynders, T, Declercq, R, McCrea, J, Dennie, J, Adkinson, NF, Shepherd, G & Gutstein, DE 2018, 'Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial', British Journal of Anaesthesia, vol. 121, no. 4, pp. 749-757. https://doi.org/10.1016/j.bja.2018.05.056
Min, K. C. ; Bondiskey, P. ; Schulz, V. ; Woo, T. ; Assaid, C. ; Yu, W. ; Reynders, T. ; Declercq, R. ; McCrea, J. ; Dennie, J. ; Adkinson, N Franklin ; Shepherd, G. ; Gutstein, D. E. / Hypersensitivity incidence after sugammadex administration in healthy subjects : a randomised controlled trial. In: British Journal of Anaesthesia. 2018 ; Vol. 121, No. 4. pp. 749-757.
@article{b619f5a3f7694f34a9e80e6158fa1fd5,
title = "Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial",
abstract = "Background: We evaluated the incidence of hypersensitivity or anaphylaxis after repeated single-dose sugammadex administration in non-anaesthetised adults. Methods: In this multicentre, double-blind study (NCT02028065), healthy volunteer subjects were randomised (2:2:1 ratio) to one of three groups to receive three repeated intravenous injections of sugammadex 4 or 16 mg kg−1, or placebo, separated by a ∼5 week intervals. Targeted hypersensitivity assessments were performed 0.5, 4, and 24 h post-dosing, and hypersensitivity signs/symptoms were referred to a blinded independent Adjudication Committee. Anaphylaxis was determined per Sampson (Criterion 1). The primary endpoint was the proportion with confirmed hypersensitivity. Results: Of 375 evaluable subjects, 25 had confirmed hypersensitivity [sugammadex 4 mg kg−1: 10/151 (6.6{\%}); sugammadex 16 mg kg−1: 14/148 (9.5{\%}); placebo: 1/76 (1.3{\%})]. The differences in incidence rates vs placebo were 5.3{\%} (95{\%} confidence interval: –0.9, 10.7) for sugammadex 4 mg kg−1 and 8.1{\%} (1.7, 14.2) for 16 mg kg−1. Incidence was similar across sugammadex doses and dosing occasions, including in subjects with reactions to previous doses. Three subjects (16 mg kg−1 group) required antihistamines/corticosteroids and discontinued the study, per protocol; symptoms resolved and no subject required epinephrine. One subject with anaphylaxis after the first 16 mg kg−1 dose recovered completely post-treatment. There were no clinically relevant anti-sugammadex antibody or tryptase findings. Conclusions: Hypersensitivity in response to sugammadex administration can occur in healthy subjects without history of previous sugammadex exposure. Hypersensitivity incidence was similar across sugammadex doses and numerically higher than placebo, with no evidence of sensitisation with repeated administration. Hypersensitivity is unlikely to be mediated through sugammadex-specific immunoglobulin G- or E-mediated mast cell stimulation in healthy volunteers. Clinical trial registration: NCT02028065.",
keywords = "anaphylaxis, hypersensitivity, neuromuscular block, sugammadex",
author = "Min, {K. C.} and P. Bondiskey and V. Schulz and T. Woo and C. Assaid and W. Yu and T. Reynders and R. Declercq and J. McCrea and J. Dennie and Adkinson, {N Franklin} and G. Shepherd and Gutstein, {D. E.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.bja.2018.05.056",
language = "English (US)",
volume = "121",
pages = "749--757",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Hypersensitivity incidence after sugammadex administration in healthy subjects

T2 - a randomised controlled trial

AU - Min, K. C.

AU - Bondiskey, P.

AU - Schulz, V.

AU - Woo, T.

AU - Assaid, C.

AU - Yu, W.

AU - Reynders, T.

AU - Declercq, R.

AU - McCrea, J.

AU - Dennie, J.

AU - Adkinson, N Franklin

AU - Shepherd, G.

AU - Gutstein, D. E.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: We evaluated the incidence of hypersensitivity or anaphylaxis after repeated single-dose sugammadex administration in non-anaesthetised adults. Methods: In this multicentre, double-blind study (NCT02028065), healthy volunteer subjects were randomised (2:2:1 ratio) to one of three groups to receive three repeated intravenous injections of sugammadex 4 or 16 mg kg−1, or placebo, separated by a ∼5 week intervals. Targeted hypersensitivity assessments were performed 0.5, 4, and 24 h post-dosing, and hypersensitivity signs/symptoms were referred to a blinded independent Adjudication Committee. Anaphylaxis was determined per Sampson (Criterion 1). The primary endpoint was the proportion with confirmed hypersensitivity. Results: Of 375 evaluable subjects, 25 had confirmed hypersensitivity [sugammadex 4 mg kg−1: 10/151 (6.6%); sugammadex 16 mg kg−1: 14/148 (9.5%); placebo: 1/76 (1.3%)]. The differences in incidence rates vs placebo were 5.3% (95% confidence interval: –0.9, 10.7) for sugammadex 4 mg kg−1 and 8.1% (1.7, 14.2) for 16 mg kg−1. Incidence was similar across sugammadex doses and dosing occasions, including in subjects with reactions to previous doses. Three subjects (16 mg kg−1 group) required antihistamines/corticosteroids and discontinued the study, per protocol; symptoms resolved and no subject required epinephrine. One subject with anaphylaxis after the first 16 mg kg−1 dose recovered completely post-treatment. There were no clinically relevant anti-sugammadex antibody or tryptase findings. Conclusions: Hypersensitivity in response to sugammadex administration can occur in healthy subjects without history of previous sugammadex exposure. Hypersensitivity incidence was similar across sugammadex doses and numerically higher than placebo, with no evidence of sensitisation with repeated administration. Hypersensitivity is unlikely to be mediated through sugammadex-specific immunoglobulin G- or E-mediated mast cell stimulation in healthy volunteers. Clinical trial registration: NCT02028065.

AB - Background: We evaluated the incidence of hypersensitivity or anaphylaxis after repeated single-dose sugammadex administration in non-anaesthetised adults. Methods: In this multicentre, double-blind study (NCT02028065), healthy volunteer subjects were randomised (2:2:1 ratio) to one of three groups to receive three repeated intravenous injections of sugammadex 4 or 16 mg kg−1, or placebo, separated by a ∼5 week intervals. Targeted hypersensitivity assessments were performed 0.5, 4, and 24 h post-dosing, and hypersensitivity signs/symptoms were referred to a blinded independent Adjudication Committee. Anaphylaxis was determined per Sampson (Criterion 1). The primary endpoint was the proportion with confirmed hypersensitivity. Results: Of 375 evaluable subjects, 25 had confirmed hypersensitivity [sugammadex 4 mg kg−1: 10/151 (6.6%); sugammadex 16 mg kg−1: 14/148 (9.5%); placebo: 1/76 (1.3%)]. The differences in incidence rates vs placebo were 5.3% (95% confidence interval: –0.9, 10.7) for sugammadex 4 mg kg−1 and 8.1% (1.7, 14.2) for 16 mg kg−1. Incidence was similar across sugammadex doses and dosing occasions, including in subjects with reactions to previous doses. Three subjects (16 mg kg−1 group) required antihistamines/corticosteroids and discontinued the study, per protocol; symptoms resolved and no subject required epinephrine. One subject with anaphylaxis after the first 16 mg kg−1 dose recovered completely post-treatment. There were no clinically relevant anti-sugammadex antibody or tryptase findings. Conclusions: Hypersensitivity in response to sugammadex administration can occur in healthy subjects without history of previous sugammadex exposure. Hypersensitivity incidence was similar across sugammadex doses and numerically higher than placebo, with no evidence of sensitisation with repeated administration. Hypersensitivity is unlikely to be mediated through sugammadex-specific immunoglobulin G- or E-mediated mast cell stimulation in healthy volunteers. Clinical trial registration: NCT02028065.

KW - anaphylaxis

KW - hypersensitivity

KW - neuromuscular block

KW - sugammadex

UR - http://www.scopus.com/inward/record.url?scp=85052097485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052097485&partnerID=8YFLogxK

U2 - 10.1016/j.bja.2018.05.056

DO - 10.1016/j.bja.2018.05.056

M3 - Article

VL - 121

SP - 749

EP - 757

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 4

ER -